Xu Cui

Hebei Medical University, Chentow, Hebei, China

Are you Xu Cui?

Claim your profile

Publications (2)3.15 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this work was to study the nasal route for the delivery of vasoactive intestinal peptide (VIP) to the brain and to evaluate the toxicity of VIP nasal spray. Mice were injected intracerebroventricularly with the aggregated Abeta25-35 to mimic Alzheimer's disease. Following administration, different groups of mice were treated over one week, and their spatial learning and memory capacities were evaluated by the Morris water maze test. The toxicity of VIP nasal spray was evaluated by examining the morphology of individual rat nasal mucosa cilia and the pathology of rat nasal mucosa. Rats receiving intranasal VIP (40 microg/ml) showed good spatial memory relative to the Abeta25-35 model group, but the escape latency did not show any statistically significant difference. Intranasal administration of VIP nasal spray (200 microg/ml) improved deficits in spatial memory to the point that test animals receiving intranasal VIP showed no statistically significant differences from the normal control group in escape latency. This indicated that the nasal spray method could increase the quantity of VIP entering the brain and protect the central nervous systems of mice. Toxicity evaluation showed that the preparation could cause minor irritation, which resolved spontaneously within a week at the end of treatment. In conclusion, VIP can be delivered successfully to the brain using the intranasal route.
    Pharmazie 02/2013; 68(1):69-74. DOI:10.1691/ph.2013.1148 · 1.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Vasoactive intestinal peptide (VIP) is a linear cationic neuropeptide composed of 28 amino acids. It belongs to the glucagon/secretin family. The biological functions of VIP are relatively broad, but it has not been well studied in the field of pharmaceutics. Especially in the selection of the way of VIP administration and the pharmaceutical formulation, the theory basis was deficient appreciably. Objective: To provide the theory basis for the pharmaceutical development of VIP, the chemical and biological stability of VIP was studied. Materials and methods: The stability of VIP in different pH values, ionic strength, temperature, artificial gastric fluid and artificial intestinal fluid was investigated, and the concentration of VIP was calculated by HPLC method. Results: The stability of VIP was pH-dependent. VIP was stable in acid and neutral solution, and almost didn't degrade during pH ≤ 7 solution. However, it was instability in basic solution and degraded completely at 30 min in pH 13 solution. Ionic strength did not affect its stability. VIP was stable in freezing conditions but it degraded at low concentration in cold storage. Furthermore, VIP degraded so quickly in artificial gastric fluid and artificial intestinal fluid that it can't be detected at 0 min. Discussion and conclusion: the chemical and biological characteristic of VIP was unstable, so it isn't suitable for oral administration.
    Drug Development and Industrial Pharmacy 06/2012; 39(12). DOI:10.3109/03639045.2012.693503 · 2.10 Impact Factor